Abstract:Surgical tumor resection may be considered for carefully selected patients. Adjuvant chemotherapy and PCI are recommended for all patients. Adjuvant TRT is currently used in patients with positive lymph nodes (pN1), because the probability of a subclinical involvement of the mediastinal lymphatic system appears to be increased in these patients.
“…Surgical resection which has been showed to improve overall survival in some studies (21) but fails to improve survival in the study by Lad et al (22) which included 340 patients with stages I to IIIB SCLC. However, some retrospective studies showed an 86% benefit of surgery for stages I and II on 5-year survival (23), a 47% benefit of surgery for stages IA to IIB (24,25), and decreased overall survival with increasing stages. Results of this study also showed that surgery improved overall survival for N0, N1, and N2 (N3 stages were excluded from the study) and postoperative radiotherapy for N2 subgroup but not for N0 and N1 subgroups.…”
Background: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period.Methods: A standardised form was completed for each patient at inclusion. Then, vital status was collected.
“…Surgical resection which has been showed to improve overall survival in some studies (21) but fails to improve survival in the study by Lad et al (22) which included 340 patients with stages I to IIIB SCLC. However, some retrospective studies showed an 86% benefit of surgery for stages I and II on 5-year survival (23), a 47% benefit of surgery for stages IA to IIB (24,25), and decreased overall survival with increasing stages. Results of this study also showed that surgery improved overall survival for N0, N1, and N2 (N3 stages were excluded from the study) and postoperative radiotherapy for N2 subgroup but not for N0 and N1 subgroups.…”
Background: The French College of General Hospital Respiratory Physicians conducted two studies that consecutively included all patients followed in participating general hospitals for primary small cell (SCLC) or non-small cell (NSCLC) lung cancer diagnosed in 2000 and 2010. These studies allow descriptive statistics and outcome assessment for SCLC and NSCLC separately and comparison over a 10-year period.Methods: A standardised form was completed for each patient at inclusion. Then, vital status was collected.
“…Lung cancer is the leading cause of cancer death for men and the third for women in Japan [2,16,17,20]. As for stage I non-small cell lung cancer (NSCLC), surgical resection results in 60-70% 5-year overall survival rates [4,9].…”
“…Esophagitis is an important side effect during thoracic radiotherapy, and becomes dose-limiting when radiation doses > 60 Gy are used, especially in combination with chemotherapy [2,4].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.